v3.23.2
Consolidated Statements of Cash Flows - USD ($)
 3 Months Ended 6 Months Ended 12 Months Ended
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Dec. 31, 2022
Cash Flows from Operating Activities          
Net loss $ (13,961,702) $ (6,937,910) $ (26,856,837) $ (15,127,708)  
Adjustments to reconcile net loss to net cash used in operating activities:          
Depreciation and amortization     2,935,067 420,630  
Amortization of intangible asset 363,750 350,000 727,500 350,000  
Noncash lease expense     218,551 53,313  
Noncash interest expense       11,870  
Stock-based compensation 700,000 800,000 1,434,527 1,713,214  
Change in fair value of common stock warrants   (1,511)   (9,290)  
Change in fair value of contingent consideration 1,100,000 (203,000) 109,500 (224,000)  
Unrealized (gain) loss on investments     (63,321) 1,431,631  
Deferred tax liability     (571,120) (3,326,000)  
Increase (decrease) in cash arising from changes in assets and liabilities, net of acquisitions:          
Accounts receivable     (179,321) (82,992)  
Other assets     (193,124) (11,013,793)  
Prepaid expenses and other current assets     217,463 1,336,620  
Grant receivable     1,524,522 (206,163)  
Contract receivables       24,526,231  
Right-of-use assets     386,336    
Deposits     60,376 10,592  
Accounts payable     (2,101,841) 3,421,220  
Deferred revenue     1,116,216 2,500  
Accrued expenses and other liabilities     (767,835) (4,719,416)  
Other long-term liabilities       2,925  
Net Cash Used In Operating Activities     (22,003,341) (1,428,616)  
Cash Flows from Investing Activities          
Purchase of short-term investments     (340,380) (1,762,833)  
Sale of short-term investments     23,514,465 28,948,785  
Purchases of property and equipment     (1,036,623) (3,350,670)  
Disposal of property and equipment     184,528    
Acquisition of Elusys Therapeutics, net of cash paid       2,719,898  
Payment of contingent consideration       (22,784,571)  
Net Cash Provided By Investing Activities     22,321,990 3,770,609  
Cash Flows from Financing Activities          
Repayments of principal under finance lease     (2,915,654) (111,146)  
Net Cash Used In Financing Activities     (2,915,654) (111,146)  
Effect of exchange rate changes on cash and cash equivalents     (865) (42,067)  
Net (Decrease) Increase in Cash and Cash Equivalents     (2,597,870) 2,188,780  
Cash and Cash Equivalents - Beginning of the Period     8,434,554 8,053,879 $ 8,053,879
Cash and Cash Equivalents - End of the Period $ 5,836,684 $ 10,242,659 5,836,684 10,242,659 $ 8,434,554
Supplemental Disclosure for Cash Flow Information:          
Right-of-use assets obtained upon operating lease commencements       704,004  
Right-of-use assets obtained upon financing lease commencements     7,789,655    
Right-of-use assets surrendered upon financing lease modifications     (3,092,408)    
Cash paid for receivable consideration included in contract receivables       20,784,571  
Supplemental disclosure of non-cash investing and financing activities:          
Purchases of property and equipment included in accounts payable     373,127    
Purchases of other assets included in accounts payable       2,345,624  
Contingent and deferred cash consideration related to Elusys acquisition       $ 45,953,685  
Increase in other assets and uncertain tax position from the finalization of Elusys' purchase accounting     1,002,904    
Increase in goodwill and deferred tax liability from the finalization of Elusys' purchase accounting     $ 571,120    

Source

PDF HTML 10-Q Filing
ZIP XLS XBRL